Navigation Links
First CyberKnife VSI System Installed at Creekside Cancer Care
Date:5/27/2010

SUNNYVALE, Calif., May 27 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced the installation of the first CyberKnife VSI System at Creekside Cancer Care in Lafayette, Colo. The CyberKnife VSI System is the newest addition to the CyberKnife product family that will allow the Creekside Cancer Care center to offer expanded cancer treatment options from radiosurgery to high-precision radiation therapy. The center expects to begin treating patients with the CyberKnife VSI System in June.

The new CyberKnife VSI System brings important advantages that will allow the Creekside Cancer Care center to broaden the range of non-invasive treatment options they offer. The time to deliver a radiosurgery plan may be reduced by up to 50 percent, with no compromise in accuracy as is seen with hybrid radiotherapy systems. In fact, the CyberKnife VSI System has advanced the ability to track and correct for tumor motion; this is especially important for treating lung cancer, and allows a greater number of patients to be treated non-invasively. This combination of speed and accuracy is unique, allowing the CyberKnife VSI System to be used for procedures ranging from world class radiosurgery to Robotic Intensity Modulated Radiation Therapy (IMRT). Doctors at the Creekside Cancer Care center will be able to deliver highly precise radiation treatments over varying treatment sessions, or fractions, to customize their care to meet the unique needs of each patient.  

"Unlike other radiotherapy or "hybrid" approaches, the CyberKnife VSI System gives us the most flexible and adaptive delivery possible utilizing 3-dimensional imaging and 6-dimensional tracking to detect tumor motion and to automatically correct for any changes in the patient or target position," said C. Kelley Simpson, M.D., of Creekside Cancer Care. "Our acquisition of the latest technology, the CyberKnife VSI, allows us to provide targeted robotic radiosurgery or radiation therapy in the most appropriate increments for each, individual patient. This allows us to better tailor our care to ensure the right amount of radiation is delivered to the right place in the right time frame for each patient, all with the same superior accuracy for which the CyberKnife is known."

"Centers like Creekside Cancer Care recognize and appreciate the opportunity that the CyberKnife VSI System presents to treat more patients, more effectively, and in the manner best suited for the patient," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The CyberKnife VSI System demonstrates our commitment and ability to continue the technological and clinical lead we've established in the radiation oncology field."

About Creekside Cancer Care

Creekside Cancer Care is a free-standing cancer care facility located in a scenic and tranquil creek side setting in the foothills of the Rocky Mountains in Lafayette, Colorado, just 30 minutes from Denver International Airport. Creekside Cancer Care boasts the most advanced clinical and health care information technologies available. The clinical focus of our extensively trained physicians and staff is to provide the best and most efficient patient centric care possible for the treatment of benign and malignant tumors throughout the body as well as functional neurological disorders. www.coloradocyberknife.com

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to deliver more than 80,000 treatments worldwide and currently 196 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to market need, clinical applications, and clinical acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2009 fiscal year, our quarterly report on Form 10-Q filed on May 6, 2010, and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ® Technologies, Inc. announces that the Journal ... of Vibration on Molar Distalization," a study that focused ... Bowman , this prospective, peer-reviewed clinical study concluded that ... speeds up molar distalization rates in the apex ... to move the upper molars into a normal, Class ...
(Date:1/17/2017)... , Jan. 17, 2017 Following an ... today praised the Food and Drug Administration,s (FDA,s) ... Human Drug Products by Pharmacies and Outsourcing Facilities." ... proposed limitation on pre-packaging -- which would have ... costs to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... DUBLIN , Jan 17, 2017 Research ... Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, ... CVD) - Global Forecast to 2021" report to their offering. ... The global ... by 2021 from USD 157.95 Billion in 2016, growing at a ...
Breaking Medicine Technology:
(Date:1/17/2017)... , ... January 17, 2017 , ... Neil H. Greco ... planning assistance to communities throughout the region, is launching a charity drive to raise ... is by far the deadliest killer in America, and is responsible for 1 in ...
(Date:1/17/2017)... ... ... SC&H Group, a leading audit, tax, and consulting firm, announced that Chris Rossi ... . Rossi is the third technology consulting leader to join SC&H Group’s IT Advisory ... practice continues to expand.     , Bringing more than 25 years of business consulting and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon ... cyber threats in real-time, today announced a strategic partnership with TechLab Security, ... Joining other Seceon partners, TechLab Security has become a strategic partner and a ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... offices in Tyler, has announced the latest beneficiary of their thriving community involvement ... nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. Donations to ...
(Date:1/17/2017)... ... ... Many people make New Year’s resolutions or renew their commitment to better health with the ... people who want to kick off 2017 with better smiles. Dr. Mondavi is offering several ... offers include: , , A new patient package for just $49, ...
Breaking Medicine News(10 mins):